• Libraries
    • Log in to:
    View Item 
    •   MSpace Home
    • Rady Faculty of Health Sciences
    • College of Medicine - B.Sc. (Med) Projects
    • View Item
    •   MSpace Home
    • Rady Faculty of Health Sciences
    • College of Medicine - B.Sc. (Med) Projects
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    iMMUNOBUllous disease and the efficacy of rituximab: A manitoba population analysis

    Thumbnail
    View/Open
    BSc(Med) Final Research Report (390.7Kb)
    Date
    2016
    Author
    Kovaltchouk, Uliana
    Metadata
    Show full item record
    Abstract
    Immunobullous diseases result from an autoimmune process in which the targets are antigens in the skin. Therapy has classically included systemic steroid and other immunosuppressants including Mycophenalate mofitil, azathioprine, and other immunosuppressant medications. Chronic use of such immunosuppressives, over the years, can often result in suppression of such disease. Rituximab, a monoclonal anti-body, has shown great promise as remittive management of immunobullous diseases. Such medications have been extensively utilized at our clinic in management of such patients. We undertake a retrospective project to characterize and classify the patient demographics, disease specific, and treatment regimen that these patients required, to gain a better understanding of the utility of Rituximab in the management of this patient population.
    URI
    http://hdl.handle.net/1993/33107
    Collections
    • College of Medicine - B.Sc. (Med) Projects [206]

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of MSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    Statistics

    View Usage Statistics

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV